Cargando…

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation

Eosinophilic granulomatosis with polyangiitis (EGPA) is systemic vasculitis caused by eosinophilia affecting small to medium-sized blood vessels, which damages the organs. Antineutrophil cytoplasmic antibody-associated vasculitis EGPA treatment guidelines added anti-interleukin-5 antibody mepolizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Mari, Yatomi, Masakiyo, Wakamatsu, Ikuo, Uno, Shogo, Hanazato, Chiharu, Masuda, Tomomi, Yamaguchi, Koichi, Aoki-Saito, Haruka, Kasahara, Norimitsu, Miura, Yosuke, Tsurumaki, Hiroaki, Hara, Kenichiro, Koga, Yasuhiko, Sunaga, Noriaki, Okada, Takuhisa, Ikota, Hayato, Hisada, Takeshi, Maeno, Toshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025129/ https://www.ncbi.nlm.nih.gov/pubmed/36950026 http://dx.doi.org/10.1016/j.rmcr.2023.101818

Ejemplares similares

A case of a patient with neurofibromatosis type I who developed pneumothorax and eosinophilic pleural effusion after suffering from COVID-19 pneumonia
por: Wakamatsu, Ikuo, et al.
Publicado: (2021)

A pregnant woman with severe dyspnoea
por: Kanbe, Mio, et al.
Publicado: (2022)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis
por: Sunaga, Noriaki, et al.
Publicado: (2022)

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome
por: Hachisu, Yoshimasa, et al.
Publicado: (2017)

The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis
por: Hachisu, Yoshimasa, et al.
Publicado: (2022)

Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients
por: Hachisu, Yoshimasa, et al.
Publicado: (2019)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Takigawa, Yuki, et al.
Publicado: (2023)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
por: Kanbe, Mio, et al.
Publicado: (2022)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
por: Nara, Mizuho, et al.
Publicado: (2019)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
por: Kai, Yoshiro, et al.
Publicado: (2022)

Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis
por: Ulu, Kadir, et al.
Publicado: (2022)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
por: Terrier, Benjamin, et al.
Publicado: (2023)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
por: Masumoto, Nami, et al.
Publicado: (2023)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Roles of Cyclic AMP Response Element Binding Activation in the ERK1/2 and p38 MAPK Signalling Pathway in Central Nervous System, Cardiovascular System, Osteoclast Differentiation and Mucin and Cytokine Production
por: Koga, Yasuhiko, et al.
Publicado: (2019)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
por: Kasahara, Norimitsu, et al.
Publicado: (2020)

17(R)‐resolvin D1 ameliorates bleomycin‐induced pulmonary fibrosis in mice
por: Yatomi, Masakiyo, et al.
Publicado: (2015)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
por: Faverio, Paola, et al.
Publicado: (2018)

Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis
por: Tsurumaki, Hiroaki, et al.
Publicado: (2019)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
por: Hattori, Keita, et al.
Publicado: (2021)

A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis
por: Quan, Michele V., et al.
Publicado: (2018)

Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab
por: Tamechika, Shin-ya, et al.
Publicado: (2021)

Anti-neutrophil Cytoplasmic Antibody-negative Eosinophilic Granulomatosis with Polyangiitis Complicated with Peripheral Neuropathy that Underwent Remission Induction with Mepolizumab Monotherapy
por: Nishihara, Masahiro, et al.
Publicado: (2023)

Penile granulomatosis with polyangiitis
por: Amico, Séverine, et al.
Publicado: (2019)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sf3pk833eio7ebana914u37383